Mr. Barry Delany:

We are very concerned, so we are putting significant resources into combatting the problem. We are engaging, of course, with the European Commission and the Scottish authorities to deal with what we see is something of concern. We conduct our own risk analysis. As we stated earlier, we have in-house experts on etymology, pathway analysis and risk analysis. We utilise that expertise in terms of being able to justify any measures that we take. Any measure must be scientifically justified before approaching the European Commission to justify implementation. In that context, that is why we closely liaise with the Scottish and our Northern Ireland colleagues to have a negotiated agreement on increased surveillance, increased inspections and some additional exclusions from where products can be traded, in the first instance. That is always consistently under review. I hope to return shortly to report on this matter to this committee and the relevant stakeholders, some of whom are seated in the Gallery. That is our current approach.